ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2522

Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations

Alejandro Balsa1, Chamaida Plasencia-Rodriguez2, Maria Gema Bonilla3, Alejandro Villalba2, Diana Peiteado2, Sara Garcia-Carazo4, Laura Nuño5, Teresa Jurado6, Emilio Martín-Mola7 and Dora Pascual-Salcedo8, 1Rheumatology, Hospital La Paz-IdiPaz, Madrid, Spain, 2Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, 3Rheumatology Unit, La Paz University Hospital, Madrid, Spain, 4Rheumatology, Hospital La Paz-Idipaz, Madrid, Spain, 5Hospital La Paz-IdiPaz, Madrid, Spain, 6Immunology, La Paz University Hospital-Idipaz, Madrid, Spain, 7Rheumatology, Hospital Universitario La Paz, Madrid, Spain, 8Immunology, La Paz University Hospital, Madrid, Spain

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Clinical Response, infliximab and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Therapeutic Strategies, Biomarkers and Predictors of Outcomes in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose To evaluate the effects of infliximab (Ifx) dose increase in active rheumatoid arthritis (RA) patients, presenting different serum infliximab concentrations.

Methods Retrospective study including 42 RA patients treated with increased Ifx following insufficient response (DAS28 > 3.2). Serum concentrations of Ifx and antibodies to Ifx (ATI) were recorded together with DAS28 and EULAR clinical response parameters throughout a year prior (T1) and after increasing dose (T2: immediately post-increase, T3: 6 months after T1 and T4:1 year after T1). Analyses were carried out with three patient groups defined by Ifx serum concentration prior to treatment enhancement: no detectable levels, (NL), low levels (LL< 1.1 µg/ml) or high levels (HL≥1.1 µg/ml). This cut-off was chosen empirically, based on most patients with Ifx levels >1.1 µg/ml experienced clinical improvement in our cohort.

Results The demographic characteristics are shown in the Table 1. Twenty patients (47.6%) were classified in NL, while 13 (30.9%) and 9 (31.4%) showed LL and HL respectively. Due to drug interference with ELISA, ATI were only detected in NL patients. DAS28 improved immediately after increasing Ifx dosage, from baseline (4.55±1.01 vs 3.95±1.22; p<0.05 after Bonferroni correction), but the improvement did not persist at 1 year (3.98±1.22; p=0.075 after Bonferroni correction). The change in DAS28 from baseline (deltaDAS28) followed a similar pattern (-0.63±1.18 at T2 to 1.17±1.45 at T4 (p<0.001))(Figure 1). Overall, 5 (13.2%) patients achieved a good response by EULAR response after the first dose increase, whereas 18 (47.4%) patients had no response. At T4, 3 (10.7%) patients showed a good response and 18 (64.3%) remained non-responders.

Conclusion These results suggest that the effectiveness of Ifx dose increase after therapeutic failure is limited, independently of pre increase serum trough infliximab concentrations.


Disclosure:

A. Balsa,

Pfizer Inc,

9;

C. Plasencia-Rodriguez,

Pfizer Inc,

2;

M. G. Bonilla,
None;

A. Villalba,
None;

D. Peiteado,
None;

S. Garcia-Carazo,
None;

L. Nuño,
None;

T. Jurado,
None;

E. Martín-Mola,
None;

D. Pascual-Salcedo,

Pfizer Inc,

2.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-infliximab-dose-increase-in-rheumatoid-arthritis-at-different-trough-concentrations/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies